Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors

MT Newswires Live

昨天

Racura Oncology (ASX:RAC) said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.

The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.

Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2664888926"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664888926\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664888926?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 08:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664888926","market":"hk","top_or_hot":-1,"title":"Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.</p><p>The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.</p><p>Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Oncology Says First South Korean Site Activated for Phase 1 Drug Candidate Trial in Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-01 08:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.</p><p>The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.</p><p>Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0757428866.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664888926","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664888926","pubTimestamp":1788222288,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU2931357623.SGD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (SGDHDG) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","RAC.AU":"RACE ONCOLOGY LTD","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","AEIS":"先进能源工业公司","BK4157":"电子设备和仪器","LU0274383776.USD":"MANULIFE GF US SMALL CAP EQUITY \"AA\" (USD) INC","BK7067":"生物科技","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK7508":"医药生物股","LU2089985449.USD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (USD) ACC"},"translate_title":"Racura Oncology 表示韩国首个研究中心已启动用于晚期实体瘤 1 期候选药物试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEIS":1.5,"RAC.AU":1},"content_text":"Racura Oncology (ASX:RAC) said Ewha Womans University Seoul Hospital in South Korea was activated as the first site in the country added to the Cardioprotection and Anticancer Synergy phase one trial of its RC220 drug candidate in combination with doxorubicin in patients with advanced solid tumors, according to a Tuesday Australian bourse filing.The second and third South Korean sites, Severance Hospital and Samsung Medical Center, are set to be activated and opened for patient enrolment on Sept. 4 and Sept. 8, respectively. The final site, Asan Medical Center, has received all regulatory and governance approvals, with site activation awaiting execution of the study contract.Pre-screening of patients began at Ewha Womans University Seoul Hospital and Severance Hospital.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}